Stock Events

Stock Events

Resverlogix 

€0.065000
0
+€0.00+4.84% 06:15 Today

Statistics

Day High
0.065
Day Low
0.065
52W High
0.13
52W Low
0.048
Volume
-
Avg. Volume
-
Mkt Cap
20.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1JanExpected
Q4 0
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-6.97MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RFS.MU. It's not an investment recommendation.
AMD
2
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap196.12B
Amgen develops similar cardiovascular treatments, competing in the same therapeutic areas as Resverlogix.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals competes in the cardiovascular and metabolic disease space, offering alternatives to Resverlogix's therapies.
Novartis
NVS
Mkt Cap293.94B
Novartis offers a range of cardiovascular drugs, directly competing with Resverlogix's pipeline.
Merck
MRK
Mkt Cap305.12B
Merck & Co. has a strong presence in the cardiovascular treatment market, making it a direct competitor.
Pfizer
PFE
Mkt Cap137.76B
Pfizer develops and markets drugs for cardiovascular diseases, competing with Resverlogix's products.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca has a portfolio of cardiovascular drugs, posing competition to Resverlogix.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb offers cardiovascular therapies, directly competing with Resverlogix's drug development efforts.
Sanofi
SNY
Mkt Cap104.13B
Sanofi has a focus on cardiovascular diseases, making it a competitor in the same market as Resverlogix.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences competes in the cardiovascular space with its range of treatments.
Abbvie
ABBV
Mkt Cap438.31B
AbbVie, through its acquisition of Allergan, has expanded its portfolio into cardiovascular diseases, competing with Resverlogix.

About

Resverlogix Corp. is an advanced-stage biotechnology company that focuses on developing therapies for medical conditions with significant unmet needs. The company's primary asset is apabetalone (RVX-208), a specialized small molecule bromodomain and extra-terminal inhibitor, which is currently undergoing Phase III clinical trials. This investigational treatment aims to address a spectrum of serious ailments, including cardiovascular disease, diabetes mellitus, chronic and end-stage kidney disease, and neurodegenerative disorders. Furthermore, Resverlogix has established a collaboration with Eversana Life Science Services, LLC. This alliance is geared towards supporting the forthcoming commercial introduction of apabetalone as a treatment for COVID-19 in both the United States and Canada. The company's operations are based out of Calgary, Canada.
Show more...
CEO
Mr. Donald J. McCaffrey
Employees
19
Country
Canada
ISIN
CA76128M1086

Listings

STU
DE
RFS.STU
MU
DE
RFS.MU
OTC Link
US
RVXCF
TO
CA
RVX.TO

0 Comments

Share your thoughts

FAQ

What is Resverlogix stock price today?▼
The current price of RFS.MU is €0.07 EUR — it has increased by +4.84% in the past 24 hours. Watch Resverlogix stock price performance more closely on the chart.
What is Resverlogix stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange Resverlogix stocks are traded under the ticker RFS.MU.
What is Resverlogix market cap?▼
Today Resverlogix has the market capitalization of 20.55M
What is Resverlogix revenue for the last year?▼
Resverlogix revenue for the last year amounts to 0 EUR.
What is Resverlogix net income for the last year?▼
RFS.MU net income for the last year is -6.97M EUR.
How many employees does Resverlogix have?▼
As of July 23, 2026, the company has 19 employees.
In which sector is Resverlogix located?▼
Resverlogix operates in the Health & Wellness sector.
When did Resverlogix complete a stock split?▼
Resverlogix has not had any recent stock splits.
Where is Resverlogix headquartered?▼
Resverlogix is headquartered in Calgary, Canada.